We recently purified and characterized from rat brain a GTPase-activating protein (GAP) specific for the Rab3 small G protein subfamily implicated in Ca 2؉ -dependent exocytosis. Rab3 GAP showed two bands with M r of about 130,000 (p130) and 150,000 (p150) on SDS-polyacrylamide gel electrophoresis. p130, but not p150, showed the catalytic activity. Because p150 was likely the subunit of Rab3 GAP, here we cloned the cDNA of p150, determined its primary structure, and characterized it. The tissue and subcellular distribution patterns of p150 and p130 were similar, and both the proteins were enriched in the synaptic soluble fraction. p150 was co-immunoprecipitated with p130 from this fraction. Recombinant p150 formed a heterodimer with recombinant p130 as estimated by sucrose density gradient ultracentrifugation. Recombinant p150 neither showed the Rab3A GAP activity nor affected the activity of recombinant p130. When p150 and p130 were co-expressed in the cells, the subcellular localization of each protein did not change. These results indicate that p150 is the noncatalytic subunit of Rab3 GAP.
The Rab family, consisting of over 30 members, belongs to the small G protein superfamily and is implicated in intracellular vesicle trafficking (for reviews, see Refs. [1] [2] [3] [4] . The Rab3 subfamily belongs to this Rab family and consists of four members, Rab3A, -B, -C, and -D (for reviews, see Refs. 5 and 6). Of these members, Rab3A and -C are present in cells with Ca 2ϩ -dependent exocytosis, particularly abundant in the neuron, although Rab3B and -C are also expressed in other types of cells. Evidence is accumulating that Rab3A is involved in Ca 2ϩ -dependent exocytosis, particularly in neurotransmitter release. Recent knock-out mice results indicate that Rab3A is not essential for Ca 2ϩ -dependent neurotransmitter release but plays two different roles: to efficiently dock synaptic vesicles to the presynaptic plasma membrane (7) and to regulate the efficiency of the fusion process (8) . It has also been reported that Rab3A is involved in the formation of long term potentiation in hippocampus (9) .
The Rab family members, including the Rab3 subfamily members, have the GDP-bound inactive and GTP-bound active forms, which are interconvertible by GDP/GTP exchange and GTPase reactions (4, 6) . The precise mechanisms of the Rab family members in the regulation of vesicle trafficking remain unknown, but the GDP/GTP cycling of the Rab family members is essential for their functions. The GDP/GTP cycling is regulated by three types of regulators, GDP/GTP exchange protein (GEP), 1 GTPase-activating protein (GAP), and GDP dissociation inhibitor (GDI) (for reviews, see Refs. 4, 6, and 10) . GEP is a regulator that stimulates the GDP/GTP exchange reaction and thereby the conversion from the GDP-bound form to the GTP-bound form, and GAP stimulates the GTPase activity and thereby the conversion from the GTP-bound form to the GDPbound form. GDI has three activities (4, 6). 1) GDI preferentially interacts with the GDP-bound form and keeps it in the GDP-bound form in the cytosol by preventing it from being converted to the GTP-bound form by the action of each GEP and from being associated with its target membrane; 2) GDI transports its complexed Rab family member to each target membrane where the GDP-bound form dissociates from GDI, followed by conversion to the GTP-bound form by the action of each GEP; and 3) after the GTP-bound form accomplishes its function, it is converted to the GDP-bound form by the action of each GAP. Once the GDP-bound form is produced, GDI forms a complex with it and translocates it to the cytosol.
Of these three types of regulators, Rab GDI is a general regulator of all the Rab family members (4, 6) . Recent studies indicate that each Rab family member has its specific GEP and GAP (11) (12) (13) (14) (15) (16) . In the case of the Rab3 subfamily, we have isolated from rat brain and characterized Rab3 GEP and GAP specific for this subfamily (13, 14) . Rab3 GEP was purified as a monomeric protein, whereas Rab3 GAP was purified as heterodimeric proteins with M r of about 130,000 (p130) and 150,000 (p150) as estimated by SDS-PAGE. p130, but not p150, showed the catalytic activity. Moreover, the purified sample of Rab3 GAP showed a M r of about 300,000 as estimated by sucrose density gradient ultracentrifugation. These results suggested that p130 is the catalytic subunit of Rab3 GAP whereas p150 is the noncatalytic subunit. In this study, to obtain the definitive evidence that p150 is the noncatalytic subunit of Rab3 GAP and to clarify the physiological function of p150, we attempted to clone the cDNA of p150, to determine its primary structure, and to characterize it.
EXPERIMENTAL PROCEDURES
Materials and Chemicals-A human brain cDNA library in ZAPII was provided by Dr. Y. Nakamura (Osaka University Medical School, Suita). Lipid-modified Rab3A was purified from the membrane fraction of Spodoptera frugiperda (Sf9) cells expressing the Rab3A cDNA (17) . His 6 -tagged p130 and p150 were expressed in Escherichia coli DE3 and purified by Ni 2ϩ -nitrilotriacetic acid-agarose column chromatography as described (14) . PC12 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 5% horse serum at 37°C in 10% CO 2 (18) . Rabbit polyclonal antibodies were generated against the glutathione S-transferase fusion protein of the N-terminal region of p130 (aa residues 1-303) and the maltose-binding protein fusion protein of the middle region of p150 (aa residues 511-850). The anti-p130 and -p150 polyclonal antibodies were affinity-purified on fusion proteins coupled to CNBr-activated Sepharose 4B and N-hydroxysuccinimide-activated Sepharose HP columns (Amersham Pharmacia Biotech), respectively. A mouse anti-Rab3A monoclonal antibody, SG-11-7, was prepared as described (19) . Hybridoma cells expressing a mouse anti-Myc monoclonal antibody (9E10) were purchased from American Type Culture Collection (Rockville, MD).
Analysis of Amino Acid Sequence of p150 -Rab3 GAP was purified from rat brain synaptic soluble fraction as described (14) . The Mono Q sample of Rab3 GAP (13 g of protein) was subjected to SDS-PAGE, the protein band corresponding to p150 was cut out from the gel and digested with a lysyl endopeptidase, and the digested peptides were separated by C18 reverse phase high pressure liquid column chromatography as described (20) . The aa sequences of the peptides were determined with a peptide sequencer (Hewlett-Packard G1005A protein sequencing system).
Molecular Cloning and Determination of Nucleotide Sequence of p150 -A set of polymerase chain reaction primers was designed from human cDNA sequence (5Ј-GGCCGGTACCAAAAAATGCATTTT-TCAAAGACCTAAC-3Ј and 5Ј-GGCCGGTACCCTAACTTGAAGGT-GATGGGCTAAATCC-3Ј). With these primers, the cDNA fragment was amplified from QUICK-Clone of human brain cDNA (CLONTECH). The authenticity of the cloned cDNA was verified by DNA sequencing (21) . The obtained fragment was used for screening a human brain cDNA library (22) . Extended sequences for the partial clones were obtained by rescreening the library by hybridization or by 5Ј-rapid amplification of cDNA ends (CLONTECH). The cDNA clones obtained were subcloned using a pBluescript plasmid, and the nucleotide sequence was determined.
Constructions of Expression Vectors-Mammalian expression plasmids pCMV-Hemagglutinin and pCMV-Myc were generated to express fusion proteins with the N-terminal Hemagglutinin and Myc epitopes, respectively (23) . The cDNA fragments encoding full-length proteins of p150 and p130 were inserted into these plasmids. These cDNA fragments were also inserted into pRSET to produce the His 6 -tagged recombinant proteins in E. coli.
Co-immunoprecipitation of p150 with p130 from Rat Brain Synaptic Soluble Fraction-Rat brain synaptic soluble fraction (2.7 mg of protein) was subjected to immunoprecipitation with 26 g of the anti-p130 polyclonal antibody bound to 40 l of protein A-Sepharose. The immunoprecipitate was subjected to SDS-PAGE, followed by protein staining with Coomassie Brilliant Blue, and immunoblotting with the anti-p130 or anti-p150 polyclonal antibody.
Complex Formation of Recombinant p130 and p150 -Recombinant p150 (50 pmol) was incubated with recombinant p130 (50 pmol) for 20 min at 4°C. Purified Rab3 GAP (50 pmol), recombinant p130 alone (50 pmol), recombinant p150 alone (50 pmol), or the mixture of recombinant p130 and p150 was subjected to ultracentrifugation using 4.8 ml of a continuous sucrose density gradient (5-40% sucrose in 20 mM Tris/HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, and 1 mM dithiothreitol). Centrifugation was performed at 220,000 ϫ g for 14 h. Fractions of 150 l each were collected. A 20-l aliquot of each fraction was subjected to SDS-PAGE, followed by protein staining with silver.
Effect of Recombinant p150 on the Catalytic Activity of Recombinant p130 -Lipid-modified Rab3A (3 pmol) was incubated for 10 min at 30°C in a reaction mixture (10 l) containing 25 mM Tris/HCl, pH 8.0, 10 mM EDTA, 5 mM MgCl 2 , 0.5 mM dithiothreitol, 0.3% CHAPS, and 1.5 M [␥-
32 P]GTP. The reaction was stopped by adding 2.5 l of 80 mM MgCl 2 . To this mixture (12.5 l), recombinant p130, recombinant p150, or a mixture of recombinant p130 and p150 was added in a total volume of 50 l and further incubated for 5 min at 30°C. The mixture was applied to a nitrocellulose filter, and the radioactivity retained on the filter was determined by Cerenkov counting.
Expression of p130 and p150 in PC12 Cells-PC12 cells were plated at a density of 8 ϫ 10 4 cells/35-mm dish and incubated for 24 h. The cells were transfected with 3 g of pCMV-Myc-p130 or pCMV-Mycp150, or co-transfected with 1.5 g of pCMV-Hemagglutinin-p130 and 1.5 g of pCMV-Myc-p150 by use of LipofectAMINE reagent (24) . Twenty-four hours after the transfection, the medium was changed to fresh medium containing 100 ng/ml nerve growth factor (18) . After the cells were further incubated for 48 h, the cells were fixed with 3.7% formaldehyde in PBS for 10 min. The fixed cells were washed with 50 mM ammonium chloride in PBS and permeabilized with PBS containing 0.2% Triton X-100 for 5 min. After being soaked in 10% FBS/PBS for 1 h, the cells were treated with the first antibodies in 10% FBS/PBS for 1 h. The cells were then washed with PBS three times, followed by incubation with the fluorescence-conjugated second antibodies in 10% FBS/PBS for 1 h. After being washed with PBS three times, the cells were examined using a confocal laser scanning microscope (LSM 410; Carl Zeiss, Oberkochen, Germany).
Other Procedures-The Northern blot sheets of poly(A) ϩ RNA from various human tissues were obtained from a commercial source (CLON-TECH) and hybridized with the whole cloned cDNA of p150. Subcellular fractionation of rat brain was carried out as described (19) . SDS-PAGE was performed as described (25) . Immunoblotting was carried out as described (26) . Protein concentrations were determined with bovine serum albumin as a reference protein as described (27) . (14), we purified Rab3 GAP from rat brain synaptic soluble fraction by column chromatographies, including Q-Sepharose, hydroxyapatite, heparin-Sepharose, and Mono Q column chromatographies. On the final Mono Q column chromatography, we detected two proteins with M r of about 130,000 and 150,000, which coincided well with the GAP activity toward Rab3A. This Mono Q sample of Rab3 GAP (13 g of protein), which was accumulated from 200 rat brains, was subjected to SDS-PAGE, and the protein band with a M r of about 150,000 (p150) was cut out from the gel and digested with a lysyl endopeptidase. The peptides were separated by C18 reverse phase high pressure liquid column chromatography. Over 25 peptide peaks were observed, and the aa sequences of three peptides (peptide-3, -15, and -16) were determined. A search with these aa sequences against GenBank TM data bases revealed that peptide-3 was included in the aa sequence deduced from the cDNA fragment isolated from the cDNA library of human fetal liver and spleen (GenBank TM accession number T82880). This cDNA fragment was amplified from double-stranded human brain cDNA by polymerase chain reaction, and overlapping cDNA clones were isolated by screening a human brain cDNA library using the obtained fragment as a probe. Sequences for the partial clones were extended by rescreening of the library by hybridization and by 5Ј-rapid amplification of cDNA ends, and we obtained a cDNA encoding a whole open reading frame of p150. In-frame stop codons in the 5Ј and 3Ј regions of the cDNA indicate that this clone contains the entire coding region. The cloned cDNA encoded a protein with a calculated M r of 156,081 and 1393 aa (GenBank TM accession number AF004828). All the aa sequences of the peptides, except 9 aa, were included in this sequence (Fig.  1) . The slight differences of the aa sequences might be because of the differences in species. The cDNA encoding p150 showed no homology to any known protein.
RESULTS

Purification of p150 and Molecular Cloning of Its cDNA-In
Tissue and Subcellular Distributions of p150 -Northern blot analysis showed that about 7.5-kilobase mRNA of p150 was ubiquitously expressed in human tissues ( Fig. 2A) . Immunoblot analysis of the subcellular fractions of rat brain indicated that p130 and p150 were enriched in the synaptic soluble fraction (Fig. 2B) . 2 In contrast, Rab3A is concentrated in the crude synaptic vesicle fraction (19) . These results indicate that the tissue and subcellular distribution patterns of p150 are similar to those of p130.
Co-immunoprecipitation of p150 with p130 from Rat Brain Synaptic Soluble Fraction-We next examined whether p150 is co-immunoprecipitated with p130 from rat brain synaptic soluble fraction. The synaptic soluble fraction was incubated with protein A-Sepharose containing the immobilized anti-p130 polyclonal antibody or rabbit IgG. Proteins with M r of about 130,000 and 150,000 were immunoprecipitated with the antip130 polyclonal antibody at a molar ratio of about 1:1 (Fig. 3A,  lane 1 ). Immunoblot analysis with the anti-p130 and -p150 polyclonal antibodies indicated that proteins with M r of about 130,000 and 150,000 were p130 and p150, respectively (Fig.  3B) . These results indicate that p150 forms a complex with p130 in the synaptic soluble fraction.
Complex Formation of Recombinant p130 and p150 -To further confirm the p130-p150 interactions, we examined these interactions using the recombinant proteins. When purified Rab3 GAP was subjected to continuous sucrose density gradient ultracentrifugation, two proteins with M r of 130,000 and 150,000 appeared in a single peak with a M r of about 300,000 as described (14) (Fig. 4A) . Recombinant p130 and p150 appeared in a single peak with a M r of about 110,000 and 170,000, respectively (Fig. 4, B and C) . When the mixture of recombinant p130 and p150 at the same molar ratio was then subjected to the same ultracentrifugation, both the proteins mostly shifted to the position with a M r of 300,000 (Fig. 4D) . The molar ratio of recombinant p130 and p150 in the peak fraction was estimated to be about 1:1 by SDS-PAGE (data not shown). These results indicate that p150 directly interacts with p130 and forms a heterodimer.
Effect of Recombinant p150 on the Catalytic Activity of Recombinant p130 -We previously reported that recombinant p130 showed the GAP activity toward the Rab3 subfamily members (14) . Because p150 indeed interacted with p130, we next examined whether recombinant p150 shows the Rab3A GAP activity or affects the activity of recombinant p130. Recombinant p150 did not show the Rab3A GAP activity under the conditions where recombinant p130 showed the activity (Fig. 5) . In addition, recombinant p150 did not affect the Rab3A GAP activity of recombinant p130.
Intracellular Localization of p130 and p150 in PC12
Cells-In the last set of experiments, we expressed p130 and p150 in various combinations in PC12 cells to examine the localization of these proteins. When p130 alone was expressed in PC12 cells and the cells were differentiated into neuron-like cells by nerve growth factor, p130 was localized at both the soma and neurites (data not shown). When p150 alone was expressed in the cells, p150 showed the same distribution (data not shown). When p150 and p130 were co-expressed, the intracellular localization of each protein did not change (data not shown). These results indicate that p150 is co-localized with p130 and that p150 does not affect the localization of p130.
DISCUSSION
In a preceding paper (14), we isolated Rab3 GAP from rat brain and characterized it. We showed that Rab3 GAP was purified as a heterodimer of p130 and p150. We showed here several lines of evidence that p130 and p150 are the catalytic and noncatalytic subunits of Rab3 GAP, respectively: 1) p150 was co-purified with p130 as a heterodimer from rat brain on various column chromatographies; 2) tissue and subcellular distribution patterns of p150 and p130 were similar; 3) p150 was co-immunoprecipitated with p130 as a complex from rat brain synaptic soluble fraction; 4) recombinant p150 and p130 formed a heterodimer; 5) expressed p150 and p130 were colocalized in differentiated PC12 cells; and 6) p150 showed no Rab3 GAP activity under the conditions where p130 showed it.
Many GAPs for the Rab family members in addition to Rab3
GAP have been isolated and characterized. These include Gyp6p (GAP for Ypt6), Gyp7p (GAP for Ypt7), and Gyp1p (GAP for Sec4 and Ypt1) and show no homology to Rab3 GAP (11, 12, 16) . It remains unknown whether these Rab GAPs other than Rab3 GAP consist of two subunits, because all of them have been isolated by use of the molecular biological methods. It may be important to examine whether the Rab GAPs other than Rab3 GAP consist of subunits. We also studied here the physiological function of p150, but p150 did not affect the Rab3 GAP activity of p130 or its localization in PC12 cells. It has been shown that the dominant active mutant of Rab3A, which is deficient in its ability to hydrolyze GTP, inhibits Ca 2ϩ -dependent exocytosis from adrenal chromaffin cells and PC12 cells (28, 29) . In isolated nerve terminals, ␣-latrotoxin induces exocytosis and concomitantly increases the GDP/GTP ratio of Rab3A (30) . These observations suggest that Rab3 GAP is essential for the Rab3A function in the docking and/or fusion processes. However, it remains unknown at which stage of these processes Rab3 GAP is activated to induce GTP hydrolysis of Rab3A and how Rab3 GAP is activated. We previously showed that the GTP-bound form of Rab3A, which is complexed with Rabphilin3, a downstream target of the Rab3 subfamily members (31) , is resistant to the Rab3 GAP activity (32) . We examined whether either p130 or p150 interacts with Rabphilin3, but we have not yet obtained the evidence supporting this interaction (data not shown). It is possible that Rab3 GAP interacts with some other protein(s) implicated in the Ca 2ϩ -dependent exocytosis through p150 and regulates GTP hydrolysis of the Rab3 subfamily members at an appropriate time of the docking and/or fusion processes. It is of crucial importance to identify such a protein. 
FIG. 4.
Complex formation of recombinant p130 and p150. Purified Rab3 GAP (50 pmol), recombinant p130 (50 pmol), recombinant p150 (50 pmol), or the mixture of recombinant p130 and p150 (50 pmol each) was subjected to continuous sucrose density gradient ultracentrifugation. An aliquot of each fraction was subjected to SDS-PAGE, followed by protein staining with silver. A, purified Rab3 GAP; B, recombinant p130 alone; C, recombinant p150 alone; D, recombinant p130 and p150. E, p130; q, p150. Arrows 1-5 indicate the positions of ␣ 2 -macroglobulin (20 S; M r 720,000), catalase (11.3 S; M r 240,000), ␥-globulin (7.4 S; M r 160,000), bovine serum albumin (4.6 S; M r 66,000), and chicken ovalbumin (3.6 S; M r 45,000), respectively. The results shown are representative of three independent experiments. 
